Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review

[1]  M. Milowsky,et al.  Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Powles,et al.  Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress). , 2022, Journal of Clinical Oncology.

[3]  Pengfei Zhang,et al.  Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma , 2022, Therapeutic advances in medical oncology.

[4]  A. Ravaud,et al.  BLADDER CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Milowsky,et al.  The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. , 2021, European urology.

[6]  C. Kundu,et al.  Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy. , 2021, European journal of pharmacology.

[7]  S. Deininger,et al.  Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy—A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin , 2021, Cancers.

[8]  M. Milowsky,et al.  Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). , 2021, Journal of Clinical Oncology.

[9]  M. Harrison,et al.  Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. , 2021, The Lancet. Oncology.

[10]  H. Seo,et al.  Emerging agents for the treatment of metastatic urothelial cancer , 2021, Investigative and clinical urology.

[11]  T. Powles,et al.  Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. , 2021, The New England journal of medicine.

[12]  A. Carrato,et al.  Novel Tyrosine Kinase Targets in Urothelial Carcinoma , 2021, International journal of molecular sciences.

[13]  R. Montironi,et al.  Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer , 2021, Cancers.

[14]  E. Heath,et al.  The biology and rationale of targeting nectin-4 in urothelial carcinoma , 2020, Nature Reviews Urology.

[15]  A. Hamid,et al.  Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients , 2020, BMC Urology.

[16]  W. Oh,et al.  Treatment of muscle‐invasive and advanced bladder cancer in 2020 , 2020, CA: a cancer journal for clinicians.

[17]  T. Powles,et al.  Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Lianhong Li,et al.  PD-1/PD-L1 pathway: current researches in cancer. , 2020, American journal of cancer research.

[19]  M. Milowsky,et al.  Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. , 2020, Journal of Clinical Oncology.

[20]  David C. Smith,et al.  EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Milowsky,et al.  EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma , 2019, Annals of Oncology.

[22]  Arash Salmaninejad,et al.  PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy , 2019, Journal of cellular physiology.

[23]  M. Galsky,et al.  Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Culine,et al.  Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Mertens,et al.  SANRA—a scale for the quality assessment of narrative review articles , 2019, Research integrity and peer review.

[26]  R. de Wit,et al.  Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. , 2020, European urology oncology.

[27]  E. Kaltenthaler,et al.  Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal , 2018, PharmacoEconomics.

[28]  Kelvin K. W. Chan,et al.  Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. , 2018, European urology.

[29]  Qingfeng Ni,et al.  Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. , 2018, Human pathology.

[30]  Yair Lotan,et al.  Bladder cancer , 2020, Nature Reviews Disease Primers.

[31]  W. Berger,et al.  Review of cancer treatment with immune checkpoint inhibitors , 2017, Wiener klinische Wochenschrift.

[32]  T. Powles,et al.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[33]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[34]  N. Agarwal,et al.  Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions , 2017, Cancers.

[35]  Y. Lotan,et al.  Bladder cancer , 2016, The Lancet.

[36]  T. Yau,et al.  Pembrolizumab (Keytruda) , 2016, Human vaccines & immunotherapeutics.

[37]  C. Law,et al.  Abstract 4914: Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses , 2016 .

[38]  F. Burkhard,et al.  Open radical cystectomy: still the gold standard for muscle invasive bladder cancer , 2015, World Journal of Urology.

[39]  L. Kiemeney,et al.  Epidemiology and risk factors of urothelial bladder cancer. , 2013, European urology.

[40]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[41]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[42]  M. Khochikar.  Treatment of locally advanced and metastatic bladder cancer , 2008, Indian journal of urology : IJU : journal of the Urological Society of India.

[43]  S. Ricci,et al.  Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .